MX2021015095A - Construcciones de proteínas de unión a antígenos y usos de estos. - Google Patents
Construcciones de proteínas de unión a antígenos y usos de estos.Info
- Publication number
- MX2021015095A MX2021015095A MX2021015095A MX2021015095A MX2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A MX 2021015095 A MX2021015095 A MX 2021015095A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding protein
- protein constructs
- binding
- dll3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858932P | 2019-06-07 | 2019-06-07 | |
| US201962888384P | 2019-08-16 | 2019-08-16 | |
| PCT/US2020/036495 WO2020247873A1 (en) | 2019-06-07 | 2020-06-05 | Antigen-binding protein constructs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015095A true MX2021015095A (es) | 2022-03-22 |
Family
ID=71899864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015095A MX2021015095A (es) | 2019-06-07 | 2020-06-05 | Construcciones de proteínas de unión a antígenos y usos de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220313845A1 (https=) |
| EP (1) | EP3980129A1 (https=) |
| JP (1) | JP2022535452A (https=) |
| CN (1) | CN114746115A (https=) |
| AU (1) | AU2020289477A1 (https=) |
| CA (1) | CA3142884A1 (https=) |
| IL (1) | IL288685A (https=) |
| MX (1) | MX2021015095A (https=) |
| WO (1) | WO2020247873A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| US20230107901A1 (en) * | 2021-10-01 | 2023-04-06 | University Of Utah Research Foundation | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| JP2025525496A (ja) * | 2022-07-08 | 2025-08-05 | イマジナブ・インコーポレーテッド | Ｄｌｌ３抗原結合構築物 |
| WO2024012524A1 (zh) * | 2022-07-14 | 2024-01-18 | 苏州宜联生物医药有限公司 | 抗体药物偶联物及其制备方法和用途 |
| EP4577578A1 (en) | 2022-08-22 | 2025-07-02 | Abdera Therapeutics Inc. | Dll3 binding molecules and uses thereof |
| TW202602935A (zh) | 2024-04-01 | 2026-01-16 | 美商米西克治療公司 | 抗原結合蛋白構築體及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| WO2011028811A2 (en) | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP5932670B2 (ja) * | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| BR112014020826A8 (pt) * | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
-
2020
- 2020-06-05 AU AU2020289477A patent/AU2020289477A1/en not_active Abandoned
- 2020-06-05 EP EP20750441.6A patent/EP3980129A1/en active Pending
- 2020-06-05 JP JP2021572559A patent/JP2022535452A/ja active Pending
- 2020-06-05 WO PCT/US2020/036495 patent/WO2020247873A1/en not_active Ceased
- 2020-06-05 US US17/616,804 patent/US20220313845A1/en active Pending
- 2020-06-05 CA CA3142884A patent/CA3142884A1/en active Pending
- 2020-06-05 MX MX2021015095A patent/MX2021015095A/es unknown
- 2020-06-05 CN CN202080055954.6A patent/CN114746115A/zh active Pending
-
2021
- 2021-12-05 IL IL288685A patent/IL288685A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535452A (ja) | 2022-08-08 |
| CA3142884A1 (en) | 2020-12-10 |
| AU2020289477A1 (en) | 2022-02-03 |
| WO2020247873A1 (en) | 2020-12-10 |
| IL288685A (en) | 2022-02-01 |
| EP3980129A1 (en) | 2022-04-13 |
| US20220313845A1 (en) | 2022-10-06 |
| CN114746115A (zh) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025011030A (es) | Construcciones de proteinas de union a antigenos y usos de estas | |
| MX2021015095A (es) | Construcciones de proteínas de unión a antígenos y usos de estos. | |
| ZA202205644B (en) | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy | |
| WO2019241430A3 (en) | Antibody-oligonucleotide conjugates | |
| WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
| EP4144372A3 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
| MX2020009116A (es) | Proteinas triespecificas de union a antigenos. | |
| AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
| WO2019242632A8 (en) | Engineered cells and uses thereof | |
| WO2020010079A3 (en) | Anti-steap1 antigen-binding protein | |
| MY202559A (en) | Anti-ctla-4 antibody and use thereof | |
| HK1231374A1 (zh) | 用於靶抗原的细胞特异性调变的方法、组合物和试剂盒 | |
| WO2017132562A8 (en) | Antigen binding proteins that bind pd-l1 | |
| EP4681726A3 (en) | Anti-par2 antibodies and uses thereof | |
| BR112021020426A2 (pt) | Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso | |
| WO2021055765A3 (en) | Multimeric antibodies with enhanced selectivity for cells with high target density | |
| ZA202206670B (en) | Anti-ly6g6d antibodies and methods of use | |
| EP4056586A4 (en) | REGULATORY T CELL SURFACE ANTIGEN EPITOPE, AND ANTIBODIES BINDING SPECIFICALLY THEREFOR | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| SA522431508B1 (ar) | hK2 مستقبل المستضدات الخيمري لـ (CAR) المضاد | |
| PH12022550035A1 (en) | Antibodies which bind to cancer cells and target radionuclides to said cells | |
| MX2025005092A (es) | Anticuerpo anti-trem2 y usos del mismo | |
| WO2023009700A3 (en) | Car-expressing immune cells that specifically target mesothelin and uses thereof | |
| MY208387A (en) | Antibodies specifically recognizing pseudomonas pcrv and uses thereof |